Jonathan MacQuittyVenture Partner at Lightspeed Ventures
Since April 2016, Dr. MacQuitty has been a Venture Partner at Lightspeed Venture Partners, a California-based venture capital firm, helping to lead their investments in life sciences and healthcare. In July 2018, Lightspeed Ventures closed on $1.8 billion in new venture and growth funds.
Dr. MacQuitty is also CEO of D2G Oncology, an oncology biotech start-up spun out of Stanford in 2018. Dr. MacQuitty previously served as CEO of Forty Seven, an immuno-oncology company, from its inception in May 2015 until April 2017. In June 2018, Forty Seven completed a $113 million IPO. In October 2018, Forty Seven published results in the New England Journal of Medicine from a clinical trial of its lead product, 5F9, in Non-Hodgkin Lymphoma.
Dr. MacQuitty has been on the Board of Personalis, a cancer genomics company since its inception in 2011 when he led the seed and then later Series A rounds. He’s currently Chair of the Board. Personalis completed a $155 million IPO in June 2019 with the stock price rising 68% on first day of trading.
Since November 2016, Dr. MacQuitty has been a board director of Teneobio, a company developing bispecific antibodies. In February 2019, Teneobio signed a strategic partnership with Abbvie on a preclinical bispecific antibody for multiple myeloma. This included a $90m million upfront payment.
From 1999 to 2014, Dr. MacQuitty was a Partner at Abingworth Management, a trans-Atlantic venture capital and investment firm focused on the life sciences. From its inception in 1988 until its acquisition in 1997, he was CEO of GenPharm International, a biotech firm focused on discovering and developing novel human type antibodies primarily for cancer. Prior to GenPharm, he was a business development executive at Genencor and Genentech.
His other board directorships have included Acorda (now NASDAQ), Dicerna (now NASDAQ), Guava (acquired), Labcyte (acquired), Myelos (acquired), Orca, ParAllele BioScience (acquired), Quantum Dot (acquired), SFJ Pharma, Sosei (now listed in Tokyo), and Sunesis (now NASDAQ). He has also served on the Board of the Biotechnology Industry Organization (BIO). Dr. MacQuitty is currently Chair of the Product Development Advisory Committee for CPRIT, the Cancer Prevention and Research Institute of Texas.
Dr. MacQuitty holds an M.A. in Chemistry from Oxford University, a Ph.D. in Chemistry from University of Sussex, and an M.B.A. from Stanford University. He is a Fellow of the Royal Society of Chemistry in London.